Agile Therapeutics, Inc. (AGRX) Receives Consensus Recommendation of “Buy” from Analysts
Agile Therapeutics, Inc. (NASDAQ:AGRX) has been given a consensus rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $10.40.
Several analysts have recently weighed in on AGRX shares. ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Royal Bank Of Canada set a $8.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a research report on Sunday, July 16th. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 target price on shares of Agile Therapeutics in a research report on Monday, May 8th. Janney Montgomery Scott reiterated a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a research report on Friday, July 21st. Finally, HC Wainwright started coverage on Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price for the company.
WARNING: This story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/12/agile-therapeutics-inc-agrx-receives-consensus-recommendation-of-buy-from-analysts.html.
Several institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics during the second quarter valued at approximately $122,000. LMR Partners LLP purchased a new position in shares of Agile Therapeutics during the second quarter valued at approximately $211,000. Dimensional Fund Advisors LP raised its position in shares of Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after buying an additional 82,213 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 43,300 shares in the last quarter. Finally, Royce & Associates LP raised its position in shares of Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares in the last quarter. Hedge funds and other institutional investors own 79.89% of the company’s stock.
Agile Therapeutics (NASDAQ:AGRX) opened at 3.30 on Friday. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.15. The firm’s 50-day moving average is $4.07 and its 200-day moving average is $3.25. The stock’s market capitalization is $95.06 million.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same period in the prior year, the company earned ($0.29) EPS. On average, equities analysts expect that Agile Therapeutics will post ($1.05) earnings per share for the current fiscal year.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.